Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies

被引:57
作者
Murphy, WJ
Koh, CY
Raziuddin, A
Bennett, M
Longo, DL
机构
[1] NCI, Intramural Res Support Program, SAIC, Frederick, MD 21702 USA
[2] NCI, Mol Immunoregulat Lab, Div Basic Sci, Frederick, MD 21701 USA
[3] Univ Texas, SW Med Ctr, Dallas, TX 75230 USA
[4] NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA
关键词
D O I
10.1034/j.1600-065X.2001.1810124.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells mediate acute rejection of bone marrow, but not solid tissue, allografts in lethally irradiated mice. Precisely how and why this rejection occurs is still unclear. In allogeneic bone marrow transplantation (BMT), a spectrum of results is possible; one result can be marrow graft failure due to host rejection of the graft by NK and T cells and, at the opposite spectrum, the occurrence of graft-versus-host disease (GVHD). Donor NK cells, however, appear capable of improving donor engraftment without giving rise to GVHD and thus may be of use as an immunotherapy following BMT. As NK-cell inhibitory receptors play a role in bone marrow cell rejection, these same inhibitory receptors may also affect NK responses towards tumor cells. It has been demonstrated that blocking the interaction of inhibitory receptors with MHC determinants on tumor cells can result in greater antitumor effects. Thus, NK cells are capable of mediating both positive and negative effects during BMT depending on whether they are of host versus donor origin and their state of activation. Understanding their role in BMT provides insights as to their physiological roles and points the way to potential clinical uses.
引用
收藏
页码:279 / 289
页数:11
相关论文
共 72 条
[1]   Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells [J].
Aguila, HL ;
Weissman, IL .
BLOOD, 1996, 87 (04) :1225-1231
[2]  
ALLAVENA P, 1985, CANCER IMMUNOL IMMUN, V19, P121
[3]   Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation [J].
Asai, O ;
Longo, DL ;
Tian, ZG ;
Hornung, RL ;
Taub, DD ;
Ruscetti, FW ;
Murphy, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (09) :1835-1842
[4]   Divergent and convergent evolution of NK-cell receptors [J].
Barten, R ;
Torkar, M ;
Haude, A ;
Trowsdale, J ;
Wilson, MJ .
TRENDS IN IMMUNOLOGY, 2001, 22 (01) :52-57
[5]   HUMAN NATURAL-KILLER CLONES ENHANCE INVITRO ANTIBODY-PRODUCTION BY TUMOR-NECROSIS-FACTOR ALPHA-INTERFERON AND GAMMA-INTERFERON [J].
BECKER, JC ;
KOLANUS, W ;
LONNEMANN, C ;
SCHMIDT, RE .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1990, 32 (02) :153-162
[6]   Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: Influence of mouse colony environment [J].
Bennett, M ;
Taylor, PA ;
Austin, M ;
Baker, MB ;
Schook, LB ;
Rutherford, M ;
Kumar, V ;
Podack, ER ;
Mohler, KM ;
Levy, RB ;
Blazar, BR .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (06) :785-790
[7]   HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [J].
Braud, VM ;
Allan, DSJ ;
O'Callaghan, CA ;
Söderström, K ;
D'Andrea, A ;
Ogg, GS ;
Lazetic, S ;
Young, NT ;
Bell, JI ;
Phillips, JH ;
Lanier, LL ;
McMichael, AJ .
NATURE, 1998, 391 (6669) :795-799
[8]   CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].
Chambers, CA ;
Kuhns, MS ;
Egen, JG ;
Allison, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594
[9]   PECULIAR IMMUNOBIOLOGY OF BONE MARROW ALLOGRAFTS .1. GRAFT REJECTION BY IRRADIATED RESPONDER MICE [J].
CUDKOWICZ, G ;
BENNETT, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 134 (01) :83-+
[10]   PECULIAR IMMUNOBIOLOGY OF BONE MARROW ALLOGRAFTS .2. REJECTION OF PARENTAL GRAFTS BY RESISTANT F1 HYBRID MICE [J].
CUDKOWICZ, G ;
BENNETT, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 134 (06) :1513-+